Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

for
Hematopoietic Cell Transplantation Recipient, Leukemia,
Location: Boston MA, Providence RI, Hartford CT, New Haven CT,
Sponsor: Children's Oncology Group

Sex: All

Age: 0+

Code: NCT00736749

Recruiting
Active & Responsive

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

for
Solid Tumor
Location: New York NY, Philadelphia PA, Washington D.C. DC,
Sponsor: Biohaven Therapeutics Ltd.

Sex: All

Age: 18+

Code: NCT06384807

Phase 1, Phase 2, Recruiting
Active & Responsive

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

for
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Location: Fairfax VA, Charleston SC, Detroit MI, Houston TX,
Sponsor: A2A Pharmaceuticals Inc.

Sex: All

Age: 18+

Code: NCT06136884

Phase 1, Recruiting
Active & Responsive

F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)

for
Oral Mucositis, Periodontal Diseases, Cancer
Location: Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 25 - 70+

Code: NCT06315855

Recruiting
Active & Responsive

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for
Autoimmune Disease, Crohn Disease, Dermatomyositis,
Location: Boston MA, New Haven CT, Mineola NY, New York NY,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03816345

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase 1, Recruiting
Active & Responsive

Decentralized Clinical Trial of Effectiveness of EnergyPoints App in Cancer Survivors

for
Cancer-related Problem/Condition, Fatigue in Cancer Survivors,
Location: New York NY
Sponsor: 5 Point App, Inc.

Sex: All

Age: 18+

Code: NCT06754722

Recruiting
Active & Responsive

Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection

for
Benign Neoplasm
Location: Corvallis OR
Sponsor: Samaritan Health Services

Sex: All

Age: 18+

Code: NCT05082441

Recruiting
Active & Responsive

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

for
Cancer, Breast Cancer, Lung Cancer, Colon Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT03702309

Recruiting
Active & Responsive

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

for
Ampulla of Vater Carcinoma, Appendix Carcinoma,
Location: Damariscotta ME, Brunswick ME, Scarborough ME,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07283939

Recruiting
Active & Responsive

Caris Biorepository Research Protocol

for
Cancer, Early Detection of Cancer, Minimal Residual Disease
Location: Ridge NY, Sparta NJ, Potsdam NY, Baltimore MD,
Sponsor: Caris Science, Inc.

Sex: All

Age: 18+

Code: NCT01499394

Recruiting
Active & Responsive

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

for
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
Location: Rockport ME, Belfast ME, Damariscotta ME, Augusta ME,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07091617

Recruiting
Active & ResponsiveNew

A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

for
Solid Tumor
Location: Seattle WA
Sponsor: Coherus Oncology, Inc.

Sex: Male

Age: 18+

Code: NCT07945821

Phase 1, Phase 2, Recruiting
Active & ResponsiveNew

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

for
Metastatic NSCLC - Non-Small Cell Lung Cancer,
Location: Fairfax VA, Canton OH, Fort Worth TX
Sponsor: Xilio Development, Inc.

Sex: All

Age: 18+

Code: NCT07688577

Phase 1, Phase 2, Recruiting
Active & ResponsiveNew

A Study of DS-3939a in Participants With Solid Tumors

for
Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer,
Location: Fairfax VA, Fayetteville AR
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT07739966

Phase 1, Phase 2, Recruiting
Active & ResponsiveNew

A Study in Patients Reporting Cannabis Use Followed With an Application-Based Cannabis Journal

for
Cancer
Location: Scarborough ME
Sponsor: Scot Remick

Sex: All

Age: 18+

Code: NCT07089225

Recruiting
Active & ResponsiveNew

Improving Adherence to Chronic Disease Medication Regimens Among Patients With Recently Diagnosed Cancer

for
Cancer
Location: Durham NC
Sponsor: Duke University

Sex: All

Age: 18+

Code: NCT07811258

Recruiting
Active & ResponsiveNew

Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease

for
Thyroid Eye Disease (TED), Graves' Disease,
Location: Wilmington NC, Orland Park IL
Sponsor: Ethyreal Bio, Inc.

Sex: All

Age: 18+

Code: NCT07885605

Phase 1, Recruiting
Active & Responsive

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

for
Advanced Solid Tumor
Location: East Providence RI, Charleston SC, Huntersville NC,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT06750185

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

for
Solid Tumor
Location: Boston MA, New Haven CT, The Bronx NY, Montreal,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT06619587

Phase 1, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial